Silence Therapeutics priced an upsized public offering expected to raise about $175 million as it advances its short interfering RNA (siRNA) pipeline. The financing was increased from an earlier plan of roughly $150 million, according to an SEC filing, and is designed to fund ongoing clinical work including divesiran, a lead program recently reported to hit a “best-case” outcome in a Phase 2 study for a rare leukemia. The offering includes about 12.96 million American depository shares priced at $13.50 each. The capital raise underscores continued market demand for RNAi platforms when clinical readouts suggest differentiated efficacy or a favorable risk profile. For Silence, the immediate focus is sustaining development momentum across its siRNA franchise while preserving runway for next-stage studies and potential partnering discussions, typical for mid-to-late clinical-stage RNA therapeutics.